CD38 Drives Progress of Osteoarthritis by Affecting Cartilage Homeostasis.

Abstract

OBJECTIVE:

To observe expression of CD38, a key modulator of nicotinamide dinucleotide (NAD+) metabolism in mice with knee osteoarthritis, and protective effect of CD38 inhibition during the osteoarthritis (OA) development.

METHOD:

The destabilization of the medial meniscus (DMM) model was performed in mice to mimic the process of OA. Immunofluorescence of CD38 was performed to evaluate its response during the OA process. Limb bud-derived mesenchymal cells were isolated for micromass culture. 100 nM or 1 μM CD38 inhibitor (78c) treatment for 14 days and CD38 sgRNA infection were then used to explore the effects of chondrogenic differentiation via Alcian blue staining. The expressions of chondrogenic markers were detected using RT-PCR and Western blot. To explore the protective effect of CD38 inhibitor on cartilage degradation during OA in vivo, a CD38 inhibitor was injected into the knee joint after DMM operations. Micro-CT analysis and Safranin O-fast green staining were used to evaluate subchondral bone micro-architecture changes and cartilage degeneration.

RESULTS:

Compared to the control group, the CD38 expression in superficial cartilage was obviously increased in DMM group (P < 0.05). During the normal chondrogenic differentiation, the extracellular matrix formed and expression of Sox9, Col2, aggrecan increased apparently while CD38 expression decreased, which could be reversed with ablation of CD38 in limb bud-derived mesenchymal cells. Consistent with findings in vitro, CD38 blockage via CD38 inhibitor injection protected against osteosclerosis in medial subchondral bone and cartilage degeneration in DMM-induced experimental mice. Compared to the Sham group, DMM mice showed significantly increased values of BV and BV/TV in subchondral bone (P < 0.05) and Mankin score, which could be rescued by 78c treatment (P < 0.05). Also the CD38 inhibitor contributed to homeostasis of anabolism and catabolism by upregulating Sox9, Col2, aggrecan and downregulating Runx2, Col10 and Mmp13.

CONCLUSION:

This study primarily implicates CD38 as an important regulator of chondrogenic differentiation. Inhibition of CD38 demonstrated protection against cartilage degeneration, which suggests that CD38 could be a potential therapeutic target for OA.

• Authors: Jin-Jin Ma, Jun Ying, Jin-Yu Wang, Tao-Tao Xu, Han-Ting Xia, Hong-Ting Jin, Lu-Wei Xiao, Wen-Jun Shang, Wei-Qian Wang, Jian-Yin Feng
• Journal: Orthopaedic surgery (Orthop Surg) Vol. 14 Issue 5 Pg. 946-954 (May 2022) ISSN: 1757-7861 [Electronic] Australia
• PMID: 35441488 (Publication Type: Journal Article)
• Copyright: © 2022 The Authors. Orthopaedic Surgery published by Tianjin Hospital and John Wiley & Sons Australia, Ltd.

Chemical References

• Aggrecans
• Membrane Glycoproteins
• Cd38 protein, mouse
• ADP-ribosyl Cyclase 1

Topics

• ADP-ribosyl Cyclase 1 (metabolism)
• Aggrecans
• Animals
• Cartilage, Articular (physiopathology)
• Chondrocytes
• Disease Models, Animal
• Homeostasis
• Membrane Glycoproteins (metabolism)
• Menisci, Tibial (surgery)
• Mice
• Osteoarthritis, Knee (metabolism)